1. Home
  2. SON vs BLTE Comparison

SON vs BLTE Comparison

Compare SON & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sonoco Products Company

SON

Sonoco Products Company

N/A

Current Price

$56.47

Market Cap

5.6B

ML Signal

N/A

Logo Belite Bio Inc

BLTE

Belite Bio Inc

N/A

Current Price

$151.72

Market Cap

6.0B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SON
BLTE
Founded
1899
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Containers/Packaging
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.6B
6.0B
IPO Year
2014
2021

Fundamental Metrics

Financial Performance
Metric
SON
BLTE
Price
$56.47
$151.72
Analyst Decision
Buy
Strong Buy
Analyst Count
9
7
Target Price
$60.13
$198.00
AVG Volume (30 Days)
876.2K
147.0K
Earning Date
04-21-2026
05-08-2026
Dividend Yield
4.39%
N/A
EPS Growth
510.30
N/A
EPS
0.68
N/A
Revenue
$7,518,753,000.00
N/A
Revenue This Year
$0.10
N/A
Revenue Next Year
$1.82
$492.11
P/E Ratio
$83.40
N/A
Revenue Growth
41.72
N/A
52 Week Low
$38.65
$62.18
52 Week High
$60.67
$200.00

Technical Indicators

Market Signals
Indicator
SON
BLTE
Relative Strength Index (RSI) 46.05 44.35
Support Level $55.38 $146.94
Resistance Level $58.08 $161.17
Average True Range (ATR) 1.26 7.15
MACD -0.30 -1.67
Stochastic Oscillator 0.00 4.70

Price Performance

Historical Comparison
SON
BLTE

About SON Sonoco Products Company

Sonoco Products Co is engaged in the manufacture and supply of consumer and industrial packaging products, offering paper, metal, and plastic packaging solutions across multiple end markets. The company has two reportable segments: Consumer Packaging and Industrial Paper Packaging. The Consumer Packaging segment provides rigid packaging solutions mainly for food, beverage, household, personal care, and pharmaceutical products, while the Industrial Paper Packaging segment produces paper-based packaging materials such as tubes, cores, and protective packaging, supported by paper mills and recycling operations, serving industrial and consumer markets. It generates the majority of its revenue from the Consumer Packaging segment.

About BLTE Belite Bio Inc

Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.

Share on Social Networks: